Today before the opening bell, SmallCapVoice.com, Inc. announced that a new audio interview with True 2 Beauty Inc., a leading manufacturer and distributor of male sexual potency pills and liquid products in the United States, is now available for playback.
The interview can be heard at http://smallcapvoice.com/blog/11-19-10-audio-interview-with-true-2-beauty-inc-pink-sheets-trtb
A recognized corporate investor relations firm, with clients nationwide, SmallCapVoice is known for its ability to help emerging growth companies build a following among retail and institutional investors. The firm offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools include stock charts, stock alerts, and client information sheets that can assist with investing in stocks that are traded on the OTC BB and Pink Sheets.
True 2 Beauty, Inc. is a leading manufacturer and distributor of sexual potency pills and liquid products in the United States, with expansion efforts underway in other parts of the world. The company’s line of current products currently include Libigrow (for men), Libigirl (for women), Libiliquid Shots and Libiliquid Relaxation Drinks. Made from only natural ingredients, the products are regarded as the most powerful over the counter herbal sexual and performance supplements available on the market.
About QualityStocks:
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://Gotstocks.QualityStocks.net
Please see disclaimer on QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment